<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398879</url>
  </required_header>
  <id_info>
    <org_study_id>Perifosine 211</org_study_id>
    <nct_id>NCT00398879</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients</brief_title>
  <official_title>A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory phase 2, randomized placebo-controlled trial with stratification for
      disease and chemotherapy type. The study is subsequently closed to enrollment in all arms
      except patients with metastatic colorectal cancer which would be randomized to either
      capecitabine plus perifosine or capecitabine alone.

      The effects of perifosine may be manifested by increased time to progression, tumor
      regression reflected in partial or complete responses, or a combination of these outcomes.
      The primary goal of this trial is to obtain a preliminary and objective assessment of the
      effects of perifosine on time to progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory phase 2, randomized placebo-controlled trial with stratification for
      disease and chemotherapy type. If there is any evidence of improved time to progression in
      any tumor type with any of the drugs to be evaluated, the initial study or component(s) of
      the study will be expanded to increase the certainty that this is an effect of perifosine. If
      there is compelling evidence of benefit from this study, a phase 3 trial will be conducted to
      obtain proof of principle.

      Primary Study Objectives:

      To determine the time to tumor progression when receiving single agent chemotherapy
      (capecitabine) in combination with perifosine in comparison to patients receiving single
      agent chemotherapy (capecitabine) alone (i.e., with placebo).

      Secondary Study Objectives:

        -  To determine the toxicity of single agent chemotherapy in combination with perifosine.

        -  To compare the time to progression of chemotherapy in combination with placebo to
           historical experience.

        -  Overall survival will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of perifosine on time to progression</measure>
    <time_frame>Every 12 weeks</time_frame>
    <description>Time to progression will be measured from the first day of study drug until progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Every 12 weeks</time_frame>
    <description>Determination of the toxicity of single agent chemotherapy in combination with perifosine. Toxicity evaluation is to be performed throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of time to progression to historical experience</measure>
    <time_frame>Every 12 weeks</time_frame>
    <description>To compare the time to progression of chemotherapy in combination with placebo to historical experience.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">381</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Perifosine + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Perifosine Placebo + Capecitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perifosine</intervention_name>
    <description>Perifosine 50 mg/d qd</description>
    <arm_group_label>Arm 1: Perifosine + Capecitabine</arm_group_label>
    <other_name>D-21266</other_name>
    <other_name>KRX-0401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks</description>
    <arm_group_label>Arm 1: Perifosine + Capecitabine</arm_group_label>
    <arm_group_label>Arm 2: Perifosine Placebo + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Perifosine Placebo</intervention_name>
    <description>Placebo to Perifosine 50 mg/d qd</description>
    <arm_group_label>Arm 2: Perifosine Placebo + Capecitabine</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the treating physician, treatment with one of the following regimens
             should represent an appropriate treatment for the patient.

             - Capecitabine 825 mg/m2 BID days 1 - 14 q 3 weeks

          2. Patients should have a histologically or cytologically confirmed diagnosis of
             colorectal cancer.

          3. Patients must have received at least one but no more than two prior chemotherapy
             regimen(s) for the treatment of metastatic or recurrent disease.

          4. ECOG performance status 0 or 1.

               -  Leukocytes &gt;= 4,000/μL

               -  absolute neutrophil count &gt;= 1,500/ μL

               -  platelets &gt;= 100,000/ μL

               -  HCT &gt; 28% (with or without growth factor support)

               -  Creatinine &lt;= 2.5 mg/dl

               -  total bilirubin &lt; 1.5 x upper limit of normal

               -  transaminase &lt; 2.5 x upper limit of normal

          5. Patients must have recovered from acute toxicity—excluding alopecia—related to prior
             therapy, including surgery or radiotherapy.

          6. Patients with brain metastases may be admitted, provided the disease has been treated
             and been stable for 2 months.

          7. Patients must have ability to understand and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          1. Patients receiving any other investigational agents or devices.

          2. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to perifosine (miltefosine or edelfosine).

          3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, psychiatric illness, or social situations that would limit compliance with
             study requirements.

          4. HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study due to potential pharmacokinetic interactions with perifosine.

          5. Patients with a history of unstable or newly diagnosed angina pectoris, recent
             myocardial infarction (within 6 months of enrollment), or New York Heart Assoc. class
             II - IV congestive heart failure.

          6. Female patients who are pregnant or lactating are ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Henderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Online Collaborative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Deer Park</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Soquel</city>
        <state>California</state>
        <zip>95703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Middletown</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Sebastian</city>
        <state>Florida</state>
        <zip>32958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Branson</city>
        <state>Missouri</state>
        <zip>65616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Armonk</city>
        <state>New York</state>
        <zip>10504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Pottsville</city>
        <state>Pennsylvania</state>
        <zip>17901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOI Pharmaceuticals Investigative Site</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L, Richards DA. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2011 Nov 20;29(33):4394-400. doi: 10.1200/JCO.2011.36.1980. Epub 2011 Oct 3.</citation>
    <PMID>21969495</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2006</study_first_submitted>
  <study_first_submitted_qc>November 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <disposition_first_submitted>March 12, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 12, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 14, 2018</disposition_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

